LL, H., JS, E., JW, K., RM, H., G, A., A, B., . . . CG, S. (2026). Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024: Erratum. The Pediatric infectious disease journal, 45(4), 384. https://doi.org/10.1097/INF.0000000000005155
Chicago Style (17th ed.) CitationLL, Hammitt, et al. "Nirsevimab Is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024: Erratum." The Pediatric Infectious Disease Journal 45, no. 4 (2026): 384. https://doi.org/10.1097/INF.0000000000005155.
MLA (9th ed.) CitationLL, Hammitt, et al. "Nirsevimab Is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024: Erratum." The Pediatric Infectious Disease Journal, vol. 45, no. 4, 2026, p. 384, https://doi.org/10.1097/INF.0000000000005155.
